Rare ashy dermatosis‐like hyperpigmentation associated with osimertinib
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14383
Abstract: Osimertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR‐TKI and is widely used as the first‐line treatment for EGFR mutation‐positive non‐small cell lung cancer. Pigmentary changes caused… read more here.
Keywords: dermatosis like; ashy dermatosis; like hyperpigmentation; rare ashy ... See more keywords